Company intelligence / Profile preview
Alchemab Therapeutics
Cambridge, England, United Kingdomalchemab.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently advancing pre-clinical programs, including a novel antibody for Parkinson's disease supported by the Michael J. Fox Foundation and collaborating with Lilly on ALS therapeutics
- Therapeutic areas
- OncologyNeurology
- Modalities
- Antibody therapeutics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Eli Lilly (ALS therapeutics)AstraZeneca (prostate cancer)Medicines Discovery CatapultNVIDIA (using Cambridge-1 supercomputer)
Beyond the preview
Go deeper on Alchemab Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alchemab Therapeutics.